More than 125 million people worldwide suffer from some form of psoriasis. If you’ve struggled with your skin health this ...

Despite these limitations, the researchers believe the study confirmed the efficacy and safety of bimekizumab and brodalumab ...

Roflumilast demonstrated effectiveness and safety in treating psoriasis, with added benefits for patients with comorbidities.

Dr Grant said: “I recommend keeping a close eye on dry or cracked skin as it can be a telltale sign of psoriasis. Dry skin ...

SELARSDI is approved for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis in adults and ...

Bristol Myers Squibb today announced new five-year results from the POETYK PSO long-term extension (LTE) trial of Sotyktu (deucravacitinib) treatment in adult patients with moderate-to-severe plaque ...

In patients who were treated continuously with Sotyktu, clinical response rates were maintained from Year 1 to Year 5, including Psoriasis Area ... of enduring chronic symptoms and disease ...

How one Big Pharma ad campaign is incorporating diversity as a driving force in improving the ways drugs are marketed directly to the patients that need them.

Psoriasis, a chronic skin condition that causes inflammation in the form of raised plaques and scales on the body, affects more than 3% of the U.S. adult population. Symptoms often begin between ...